Akebia director gets 214,400 stock options

Akebia Therapeutics director Philip J. Vickers received a grant of stock options covering 214,400 shares of common stock.

Rhea-AI Filing Summary

Akebia Therapeutics director Philip J. Vickers received a grant of stock options covering 214,400 shares of common stock. The options have an exercise price of $1.41 per share and expire on April 1, 2036. This is a compensation award, not an open-market purchase.

According to the company’s 2023 Plan and its Fifth Amended and Restated Non-Employee Director Compensation Program, one third of the options will vest on the first anniversary of the grant date. The remaining two thirds will vest in equal installments on the first day of each calendar quarter thereafter, if he continues serving the company.

Insider Trade Summary

Grant/Award: 214,400 shares

Grant/Award 1 txn

Insider Vickers Philip J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	214,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 214,400 contracts (Direct)

Footnotes (1)

1. F1. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options granted: 214,400 options Exercise price: $1.41 per share Underlying shares: 214,400 shares +2 more

5 metrics

Options granted 214,400 options Stock Option (Right to buy) grant to director Philip J. Vickers

Exercise price $1.41 per share Conversion or exercise price of the stock option grant

Underlying shares 214,400 shares Common stock underlying the granted stock options

Expiration date April 1, 2036 Option expiration for the stock option grant

Post-grant derivative holdings 214,400 options Total derivative securities following the reported transaction

Key Terms

Stock Option (Right to buy), 2023 Plan, Fifth Amended and Restated Non-Employee Director Compensation Program, grant date, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

2023 Plan financial

"was granted by the Issuer pursuant to the 2023 Plan"

Fifth Amended and Restated Non-Employee Director Compensation Program financial

"as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program"

grant date financial

"on the first anniversary of the grant date and the remaining"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vest financial

"The Stock Option will vest over three years: 33 1/3 %"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Akebia Therapeutics (AKBA) director Philip J. Vickers receive in this Form 4?

He received a grant of stock options for 214,400 shares of Akebia common stock. This award is part of the company’s non-employee director compensation and does not involve an open-market stock purchase or sale.

What is the exercise price of the new Akebia (AKBA) stock options?

The options have an exercise price of $1.41 per share. This means Vickers can buy Akebia common stock at $1.41 once the options vest, regardless of the market price at that time, until the options expire.

How do the 214,400 Akebia (AKBA) stock options vest for Philip J. Vickers?

One third of the options vest on the first anniversary of the grant date. The remaining two thirds vest in equal installments on the first day of each calendar quarter, as long as he continues serving Akebia as a director.

When do Philip J. Vickers’ Akebia (AKBA) stock options expire?

The stock options expire on April 1, 2036. After this expiration date, any unexercised options will no longer be valid, so they must be exercised before that date once vested to have value.

Is this Akebia (AKBA) Form 4 transaction an open-market buy or sell of shares?

No, it is a grant of stock options as compensation, coded as an acquisition (A). Vickers did not buy or sell shares in the market; he received the right to purchase shares in the future at a fixed price.

Under what plan were the Akebia (AKBA) stock options granted to Philip J. Vickers?

The options were granted under Akebia’s 2023 Plan, following the Fifth Amended and Restated Non-Employee Director Compensation Program. This framework governs how non-employee directors are compensated with equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vickers Philip J.

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.41	04/01/2026		A		214,400		(1)	04/01/2036	Common Stock	214,400	$0.00	214,400	D

Explanation of Responses:

1. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Carolyn M. Rucci, attorney-in-fact for Philip J. Vickers	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)